Modifier genes as therapeutics: The nuclear hormone receptor rev erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cruz, Nelly M ^a,b   Yuan, Yang ^c   Leehy, Barrett D ^a   Baid, Rinku ^d   Kompella, Uday ^d,e   DeAngelis, Margaret M ^f   Escher, Pascal ^g   Haider, Neena B ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g Institute for Research in Ophthalmology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR RECEPTOR NR1D1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENHANCED S CONE SYNDROME; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC ASSOCIATION; HISTOPATHOLOGY; IN VIVO STUDY; MODIFIER GENE; MOLECULAR GENETICS; MOUSE; MOUSE STRAIN; NONHUMAN; NR1D1 GENE; NR2E3 GENE; RETINA CONE; RETINA DEGENERATION; RETINITIS PIGMENTOSA; TRANSCRIPTION REGULATION;

ANIMALS; EYE DISEASES, HEREDITARY; GENETIC THERAPY; HUMANS; MICE; MICE, TRANSGENIC; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; ORPHAN NUCLEAR RECEPTORS; RETINAL DEGENERATION; RETINITIS PIGMENTOSA; VISION DISORDERS;

EID: 84900458286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087942     Document Type: Article

References (56)

1. Wolf U (1997) Identical mutations and phenotypic variation. Hum Genet 100: 305-321.
2. Houlston RS, Tomlinson IP (1998) Modifier genes in humans: strategies for identification. Eur J Hum Genet 6: 80-88. (Pubitemid 28101701)
3. Cutting GR (2010) Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 1214: 57-69.
4. Collaco JM, Cutting GR (2008) Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 14: 559-566.
5. Bergren SK, Chen S, Galecki A, Kearney JA (2005) Genetic modifiers affecting severity of epilepsy caused by mutation of sodium channel Scn2a. Mamm Genome 16: 683-690. (Pubitemid 41484213)
6. Bergren SK, Rutter ED, Kearney JA (2009) Fine mapping of an epilepsy modifier gene on mouse Chromosome 19. Mamm Genome 20: 359-366.
7. Djousse L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, et al. (2004) Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 5: 109-114. (Pubitemid 38828670)
8. Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, et al. (2003) A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet 73: 682-687. (Pubitemid 37076283)
9. Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, et al. (2006) Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet 15: 2015-2024. (Pubitemid 43983275)
10. Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, et al. (2006) The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 7: 27-30. (Pubitemid 43327681)
11. Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, et al. (2006) Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. Hum Genet 120: 285-292. (Pubitemid 44204017)
12. Kearney JA (2011) Genetic modifiers of neurological disease. Curr Opin Genet Dev 21: 349-353.
13. Haider NB, Ikeda A, Naggert JK, Nishina PM (2002) Genetic modifiers of vision and hearing. Hum Mol Genet 11: 1195-1206. (Pubitemid 34567500)
14. Yan D, Liu XZ (2010) Modifiers of hearing impairment in humans and mice. Curr Genomics 11: 269-278.
15. Hamilton BA, Yu BD (2012) Modifier genes and the plasticity of genetic networks in mice. PLoS Genet 8: e1002644.
16. Zernant J, Kulm M, Dharmaraj S, den Hollander AI, Perrault I, et al. (2005) Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. Invest Ophthalmol Vis Sci 46: 3052-3059. (Pubitemid 44264287)
17. Passerini I, Sodi A, Giambene B, Menchini U, Torricelli F (2007) Phenotypic intrafamilial variability associated with S212G mutation in the RDS/peripherin gene. Eur J Ophthalmol 17: 1000-1003. (Pubitemid 351262917)
18. Walia S, Fishman GA, Swaroop A, Branham KE, Lindeman M, et al. (2008) Discordant phenotypes in fraternal twins having an identical mutation in exon ORF15 of the RPGR gene. Arch Ophthalmol 126: 379-384. (Pubitemid 351398462)
19. Fahim AT, Bowne SJ, Sullivan LS, Webb KD, Williams JT, et al. (2011) Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to RPGR mutations. PLoS One 6: e23021.
20. Haider NB, Jacobson SG, Cideciyan AV, Swiderski R, Streb LM, et al. (2000) Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet 24: 127-131. (Pubitemid 30094711)
21. Schorderet DF, Escher P (2009) NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). Hum Mutat 30: 1475-1485.
22. Gerber S, Rozet JM, Takezawa SI, dos Santos LC, Lopes L, et al. (2000) The photoreceptor cell-specific nuclear receptor gene (PNR) accounts for retinitis pigmentosa in the Crypto-Jews from Portugal (Marranos), survivors from the Spanish Inquisition. Hum Genet 107: 276-284.
23. Sharon D, Sandberg MA, Caruso RC, Berson EL, Dryja TP (2003) Shared mutations in NR2E3 in enhanced S-cone syndrome, Goldmann-Favre syndrome, and many cases of clumped pigmentary retinal degeneration. Arch Ophthalmol 121: 1316-1323. (Pubitemid 37128411)
24. Coppieters F, Leroy BP, Beysen D, Hellemans J, De Bosscher K, et al. (2007) Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet 81: 147-157. (Pubitemid 47001164)
25. Gire AI, Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, et al. (2007) The Gly56Arg mutation in NR2E3 accounts for 1-2% of autosomal dominant retinitis pigmentosa. Mol Vis 13: 1970-1975. (Pubitemid 350001956)
26. Cheng H, Khanna H, Oh EC, Hicks D, Mitton KP, et al. (2004) Photoreceptor-specific nuclear receptor NR2E3 functions as a transcriptional activator in rod photoreceptors. Hum Mol Genet 13: 1563-1575. (Pubitemid 39136713)
27. Haider NB, Demarco P, Nystuen AM, Huang X, Smith RS, et al. (2006) The transcription factor Nr2e3 functions in retinal progenitors to suppress cone cell generation. Vis Neurosci 23: 917-929. (Pubitemid 46456698)
28. Peng GH, Ahmad O, Ahmad F, Liu J, Chen S (2005) The photoreceptor- specific nuclear receptor Nr2e3 interacts with Crx and exerts opposing effects on the transcription of rod versus cone genes. Hum Mol Genet 14: 747-764. (Pubitemid 40403272)
29. Corbo JC, Cepko CL (2005) A hybrid photoreceptor expressing both rod and cone genes in a mouse model of enhanced S-cone syndrome. PLoS Genet 1: e11.
30. Cheng H, Aleman TS, Cideciyan AV, Khanna R, Jacobson SG, et al. (2006) In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development. Hum Mol Genet 15: 2588-2602. (Pubitemid 44288688)
31. Webber AL, Hodor P, Thut CJ, Vogt TF, Zhang T, et al. (2008) Dual role of Nr2e3 in photoreceptor development and maintenance. Exp Eye Res 87: 35-48.
32. Haider NB, Mollema N, Gaule M, Yuan Y, Sachs AJ, et al. (2009) Nr2e3-directed transcriptional regulation of genes involved in photoreceptor development and cell-type specific phototransduction. Exp Eye Res 89: 365-372.
33. Mollema N, Haider NB (2010) Focus on molecules: nuclear hormone receptor Nr2e3: impact on retinal development and disease. Exp Eye Res 91: 116-117.
34. Chen F, Figueroa DJ, Marmorstein AD, Zhang Q, Petrukhin K, et al. (1999) Retina-specific nuclear receptor: A potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and Muller glial cells. Proc Natl Acad Sci U S A 96: 15149-15154. (Pubitemid 30019780)
35. Escher P, Gouras P, Roduit R, Tiab L, Bolay S, et al. (2009) Mutations in NR2E3 can cause dominant or recessive retinal degenerations in the same family. Hum Mutat 30: 342-351.
36. Bandah D, Merin S, Ashhab M, Banin E, Sharon D (2009) The spectrum of retinal diseases caused by NR2E3 mutations in Israeli and Palestinian patients. Arch Ophthalmol 127: 297-302.
37. Akhmedov NB, Piriev NI, Chang B, Rapoport AL, Hawes NL, et al. (2000) A deletion in a photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the rd7 mouse. Proc Natl Acad Sci U S A 97: 5551-5556. (Pubitemid 30313756)
38. Haider NB, Naggert JK, Nishina PM (2001) Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice. Hum Mol Genet 10: 1619-1626. (Pubitemid 32776290)
39. Yanagi Y, Takezawa S, Kato S (2002) Distinct functions of photoreceptor cell-specific nuclear receptor, thyroid hormone receptor beta2 and CRX in one photoreceptor development. Invest Ophthalmol Vis Sci 43: 3489-3494. (Pubitemid 35334357)
40. Haider NB, Zhang W, Hurd R, Ikeda A, Nystuen AM, et al. (2008) Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity. Mamm Genome 19: 145-154.
41. Zamir I, Harding HP, Atkins GB, Horlein A, Glass CK, et al. (1996) A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol 16: 5458-5465. (Pubitemid 26315066)
42. Adelmant G, Begue A, Stehelin D, Laudet V (1996) A functional Rev-erb alpha responsive element located in the human Rev-erb alpha promoter mediates a repressing activity. Proc Natl Acad Sci U S A 93: 3553-3558.
43. Kakizawa T, Nishio S, Triqueneaux G, Bertrand S, Rambaud J, et al. (2007) Two differentially active alternative promoters control the expression of the zebrafish orphan nuclear receptor gene Rev-erbalpha. J Mol Endocrinol 38: 555-568. (Pubitemid 47019059)
44. Burris TP (2008) Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Mol Endocrinol 22: 1509-1520.
45. Mollema NJ, Yuan Y, Jelcick AS, Sachs AJ, von Alpen D, et al. (2011) Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional networks in the retina. PLoS One 6: e17494.
46. Forrest D, Swaroop A (2012) Minireview: the role of nuclear receptors in photoreceptor differentiation and disease. Mol Endocrinol 26: 905-915.
47. Yin L, Wang J, Klein PS, Lazar MA (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311: 1002-1005. (Pubitemid 43271727)
48. Yin L, Wu N, Lazar MA (2010) Nuclear receptor Rev-erbalpha: a heme receptor that coordinates circadian rhythm and metabolism. Nucl Recept Signal 8: e001.
49. Green CB, Besharse JC (2004) Retinal circadian clocks and control of retinal physiology. J Biol Rhythms 19: 91-102. (Pubitemid 38366882)
50. Storch KF, Paz C, Signorovitch J, Raviola E, Pawlyk B, et al. (2007) Intrinsic circadian clock of the mammalian retina: importance for retinal processing of visual information. Cell 130: 730-741. (Pubitemid 47268056)
51. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248. (Pubitemid 351724453)
52. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20: 999-1004.
53. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, et al. (2009) Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361: 725-727.
54. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
55. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, et al. (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9-24.
56. Matsuda T, Cepko CL (2004) Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A 101: 16-22. (Pubitemid 38084195)